Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'

J Hepatol. 2022 Aug;77(2):567-568. doi: 10.1016/j.jhep.2022.04.029. Epub 2022 May 5.

¹ Department of Biomedical and Clinical Sciences, University of Milan, Italy. Electronic address: roberto.defranchis@unimi.it.
² Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Instituts d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CIBERehd, University of Barcelona, Spain.
³ Yale University, New Haven, USA; VA-CT Healthcare System, West Haven, USA.
⁴ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
⁵ Internal Medicine IV, Universitätsklinikum Jena, Friedrich Schiller University, Jena, Germany.

No abstract available

Publication types